抗体フラグメントの世界市場レポート 2025年

抗体フラグメントの市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.6%で164億4,000万米ドルに成長します。予測期間の成長は、生物製剤の研究開発への投資の増加、より小型の抗体フォーマットへの嗜好の高まり、個別化医療への需要の高まり、自己免疫疾患への応用の拡大、二重特異性抗体の出現などに起因すると考えられます。予測期間における主な動向としては、AIを活用した創薬の統合、費用対効果の高い生産方法の開発、バイオテクノロジー企業間の提携、モノクローナル抗体技術の進歩、抗体薬物複合体の注目などが挙げられます。

対象疾患の有病率の上昇は、今後数年間の抗体フラグメント市場の成長を牽引すると予想されます。対象疾患とは、治療、治療法、研究が予防、管理、治癒を目指す特定の状態や病気を指します。一般的な対象疾患には、がん、感染症、細菌感染症などがあります。これらの疾病の有病率の増加は、主に不健康なライフスタイルや公害に起因しており、これらは身体の防御機能を弱め、慢性的な健康問題の一因となっています。抗体フラグメントは、様々な疾患に対して、非常に特異的で的を絞った多用途の治療法を提供し、多くの場合、従来の治療法に比べて副作用が少ないのが特徴です。特定のターゲットに合わせたり、設計したりすることができるため、現代医学において非常に貴重なツールとなっています。例えば、2025年1月、米国を拠点とする非営利団体American Cancer Society（米国がん協会）は、2025年には米国で新たに204万1,910人のがん患者と61万8,120人のがん関連死が発生する見込みであり、2024年の新規患者数201万1,140人、死亡者数61万1,720人から増加すると報告しています。このように、対象疾患の有病率の増加が抗体フラグメント市場の拡大に拍車をかけています。

抗体フラグメント市場の主要企業は、ヒトVH抗体フラグメントのような革新的な製品を開発するための臨床試験の実施に注力しており、がん、自己免疫疾患、感染症の治療において標的療法の有効性を向上させ、免疫原性を低減させることを目指しています。ヒトVH抗体フラグメントは、ヒト抗体の重鎖の可変ドメインで、独立して抗原に結合することができます。重要な抗原結合領域として機能することで抗体フラグメントを形成し、小型で安定した高親和性の治療・診断用抗体を作製するために、単独または他の分子と組み合わせて使用されます。例えば、2024年5月、中国の製薬会社Zai Lab Limitedは、IL-17を標的とする新規ヒトVH抗体フラグメント（Humabody）であるZL-1102の有効性と安全性を評価する国際共同第2相臨床試験を開始しました。本治療は、軽度から中等度の慢性尋常性乾癬に対する外用療法として開発されており、全身性の副作用や免疫原性反応を最小限に抑えながら、治療精度の向上を目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗体フラグメント市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗体フラグメント市場：成長率分析
• 世界の抗体フラグメント市場の実績：規模と成長、2019～2024年
• 世界の抗体フラグメント市場の予測：規模と成長、2024～2029年、2034年
• 世界の抗体フラグメント総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗体フラグメント市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• F（ab）フラグメント
• F（ab'）2フラグメント
• 単鎖可変フラグメント（scFv）
• 単一ドメイン抗体フラグメント（sdAbs）
• その他
• 世界の抗体フラグメント市場：特異性別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• ポリクローナル抗体
• 世界の抗体フラグメント市場：投与方法別、実績と予測、2019～2024年、2024～2029年、2034年
• 静脈内（IV）
• 皮下（SC）
• 経口
• 経皮
• 世界の抗体フラグメント市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• がん
• 免疫不全
• その他
• 世界の抗体フラグメント市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬会社
• バイオテクノロジー企業
• 研究機関
• 診断検査室
• 契約研究機関（CRO）
• 世界の抗体フラグメント市場：F（ab）フラグメントのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 組み換えF（ab）フラグメント
• 酵素誘導F（ab）フラグメント
• 世界の抗体フラグメント市場：F（ab'）2フラグメントのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペプシン由来F（ab'）2フラグメント
• 組み換えF（ab'）2フラグメント
• 世界の抗体フラグメント市場：単鎖可変フラグメント（scFv）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 細菌産生単鎖可変フラグメント（scFv）
• 哺乳類細胞産生単鎖可変フラグメント（scFv）
• 酵母産生単鎖可変フラグメント（scFv）
• 世界の抗体フラグメント市場：単一ドメイン抗体フラグメント（sdAbs）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラクダ科動物由来単一ドメイン抗体フラグメント（sdAbs）
• サメ由来単一ドメイン抗体フラグメント（sdAbs）
• 合成単一ドメイン抗体フラグメント（sdAbs）
• 世界の抗体フラグメント市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 二重特異性抗体フラグメント
• 多重特異性抗体フラグメント
• 融合タンパク質抗体フラグメント

第7章 地域別・国別分析

• 世界の抗体フラグメント市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の抗体フラグメント市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗体フラグメント市場：競合情勢
• 抗体フラグメント市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• UCB S.A.
• Bio-Rad Laboratories Inc.
• Genmab A/S
• WuXi Biologics Co. Ltd.
• Abcam plc
• MacroGenics Inc.
• Harbour BioMed

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗体フラグメント市場2029：新たな機会を提供する国
• 抗体フラグメント市場2029：新たな機会を提供するセグメント
• 抗体フラグメント市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antibody fragments are smaller portions of full-length antibodies that retain the ability to bind to specific antigens. These fragments are derived from antibodies and are designed to offer advantages such as greater stability, better tissue penetration, and reduced immune system reactions, making them valuable for both therapeutic and diagnostic uses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of antibody fragments include F(ab) fragments, F(ab')2 fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (sdAbs), and other types. F(ab) fragments are specific fragments that have a single antigen-binding site, lacking the Fc region to minimize immune interactions, which enhances their use in diagnostics and therapy. Antibody fragments can be classified as either monoclonal or polyclonal antibodies based on their specificity. These fragments are administered through various methods, including intravenous (IV), subcutaneous (SC), oral, or transdermal routes. They are used for treating conditions such as cancer, immunodeficiencies, and other medical disorders. The key end users of antibody fragments include pharmaceutical companies, biotechnology firms, research institutions, diagnostic labs, and contract research organizations (CROs).

The antibody fragments market research report is one of a series of new reports from The Business Research Company that provides antibody fragments market statistics, including the antibody fragments industry global market size, regional shares, competitors with the antibody fragments market share, detailed antibody fragments market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody fragments industry. This antibody fragments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody fragments market size has grown strongly in recent years. It will grow from $10.35 billion in 2024 to $11.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increased adoption of biologics, growth in cancer therapeutics, regulatory approvals for antibody-based treatments, and the expansion of biopharmaceutical research.

The antibody fragments market size is expected to see strong growth in the next few years. It will grow to $16.44 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing investment in research and development of biologics, growing preference for smaller antibody formats, rising demand for personalized medicine, expanding applications in autoimmune diseases, and the emergence of bispecific antibodies. Major trends in the forecast period include the integration of AI-driven drug discovery, development of cost-effective production methods, collaborations between biotech firms, advancements in monoclonal antibody technology, and a focus on antibody-drug conjugates.

The rising prevalence of target diseases is expected to drive the growth of the antibody fragments market in the coming years. Target diseases refer to specific conditions or illnesses that medical treatments, therapies, or research aim to prevent, manage, or cure. Common target diseases include cancer, infectious diseases, and bacterial infections. The increasing prevalence of these diseases is primarily attributed to unhealthy lifestyles and pollution, which weaken the body's defenses and contribute to chronic health issues. Antibody fragments offer highly specific, targeted, and versatile treatment options for a variety of diseases, often with fewer side effects compared to traditional therapies. Their ability to be tailored and engineered for specific targets makes them an invaluable tool in modern medicine. For example, in January 2025, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2025, the United States is expected to see 2,041,910 new cancer cases and 618,120 cancer-related deaths, up from 2,001,140 new cases and 611,720 deaths in 2024. Thus, the growing prevalence of target diseases is fueling the antibody fragments market's expansion.

Leading companies in the antibody fragments market are focusing on conducting clinical trials to develop innovative products, such as human VH antibody fragments, to improve the effectiveness of targeted therapies and reduce immunogenicity when treating cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is the variable domain of the heavy chain of a human antibody, capable of binding to antigens independently. It forms antibody fragments by serving as the crucial antigen-binding region and is often used alone or in combination with other molecules to create small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a China-based pharmaceutical company, initiated a global Phase 2 clinical trial to assess the efficacy and safety of ZL-1102, a novel human VH antibody fragment (Humabody) targeting IL-17. This treatment is being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis, aimed at improving treatment precision while minimizing systemic side effects and immunogenic responses.

In September 2024, Valerio Therapeutics S.A., a clinical-stage biotechnology company based in France, acquired Emglev Therapeutics for an undisclosed sum. This acquisition enhances Valerio Therapeutics' antibody discovery capabilities by incorporating Emglev Therapeutics' synthetic single-domain antibody (sdAb) technology, further expanding its therapeutic applications. Emglev Therapeutics is a biotechnology firm based in France, specializing in the development of synthetic single-domain antibodies (sdAb).

Major players in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

North America was the largest region in the antibody fragments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antibody fragments report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antibody fragments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody fragments market consists of revenues earned by entities by providing services such as pharmacokinetics and toxicology testing, clinical and regulatory support services, custom conjugation services, and antibody fragment production and expression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody fragments market also includes sales of diabodies and tribodies, nanobodies, antibody-based therapeutics, and diagnostic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Fragments Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody fragments market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody fragments ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody fragments market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: F(ab) Fragments; F(ab')2 Fragments; Single-Chain Variable Fragments (scFvs); Single Domain Antibody Fragments (sdAbs); Other Types
• 2) By Specificity: Monoclonal Antibody; Polyclonal Antibody
• 3) By Delivery Method: Intravenous (IV); Subcutaneous (SC); Oral; Transdermal
• 4) By Application: Cancer; Immunodeficiencies; Other Applications
• 5) By End User: Pharmaceutical Companies; Biotechnology Companies; Research Institutions; Diagnostic Laboratories; Contract Research Organizations (CROs)
• Subsegments:
• 1) By F(ab) Fragments: Recombinant F(ab) Fragments; Enzymatically Derived F(ab) Fragments
• 2) By F(ab')2 Fragments: Pepsin-Derived F(ab')2 Fragments; Recombinant F(ab')2 Fragments
• 3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs); Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs); Yeast-Produced Single-Chain Variable Fragments (scFvs)
• 4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs); Shark-Derived Single Domain Antibody Fragments (sdAbs); Synthetic Single Domain Antibody Fragments (sdAbs)
• 5) By Other Types: Bispecific Antibody Fragments; Multispecific Antibody Fragments; Fusion Protein Antibody Fragments
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibody Fragments Market Characteristics

3. Antibody Fragments Market Trends And Strategies

4. Antibody Fragments Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antibody Fragments Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antibody Fragments PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antibody Fragments Market Growth Rate Analysis
• 5.4. Global Antibody Fragments Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antibody Fragments Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antibody Fragments Total Addressable Market (TAM)

6. Antibody Fragments Market Segmentation

• 6.1. Global Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• F(ab) Fragments
• F(ab')2 Fragments
• Single-Chain Variable Fragments (scFvs)
• Single Domain Antibody Fragments (sdAbs)
• Other Types
• 6.2. Global Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• Polyclonal Antibody
• 6.3. Global Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Subcutaneous (SC)
• Oral
• Transdermal
• 6.4. Global Antibody Fragments Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Immunodeficiencies
• Other Applications
• 6.5. Global Antibody Fragments Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutions
• Diagnostic Laboratories
• Contract Research Organizations (CROs)
• 6.6. Global Antibody Fragments Market, Sub-Segmentation Of F(ab) Fragments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant F(ab) Fragments
• Enzymatically Derived F(ab) Fragments
• 6.7. Global Antibody Fragments Market, Sub-Segmentation Of F(ab')2 Fragments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pepsin-Derived F(ab')2 Fragments
• Recombinant F(ab')2 Fragments
• 6.8. Global Antibody Fragments Market, Sub-Segmentation Of Single-Chain Variable Fragments (scFvs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial-Produced Single-Chain Variable Fragments (scFvs)
• Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs)
• Yeast-Produced Single-Chain Variable Fragments (scFvs)
• 6.9. Global Antibody Fragments Market, Sub-Segmentation Of Single Domain Antibody Fragments (sdAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Camelid-Derived Single Domain Antibody Fragments (sdAbs)
• Shark-Derived Single Domain Antibody Fragments (sdAbs)
• Synthetic Single Domain Antibody Fragments (sdAbs)
• 6.10. Global Antibody Fragments Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bispecific Antibody Fragments
• Multispecific Antibody Fragments
• Fusion Protein Antibody Fragments

7. Antibody Fragments Market Regional And Country Analysis

• 7.1. Global Antibody Fragments Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antibody Fragments Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antibody Fragments Market

• 8.1. Asia-Pacific Antibody Fragments Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antibody Fragments Market

• 9.1. China Antibody Fragments Market Overview
• 9.2. China Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antibody Fragments Market

• 10.1. India Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antibody Fragments Market

• 11.1. Japan Antibody Fragments Market Overview
• 11.2. Japan Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antibody Fragments Market

• 12.1. Australia Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antibody Fragments Market

• 13.1. Indonesia Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antibody Fragments Market

• 14.1. South Korea Antibody Fragments Market Overview
• 14.2. South Korea Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antibody Fragments Market

• 15.1. Western Europe Antibody Fragments Market Overview
• 15.2. Western Europe Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antibody Fragments Market

• 16.1. UK Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antibody Fragments Market

• 17.1. Germany Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antibody Fragments Market

• 18.1. France Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antibody Fragments Market

• 19.1. Italy Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antibody Fragments Market

• 20.1. Spain Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antibody Fragments Market

• 21.1. Eastern Europe Antibody Fragments Market Overview
• 21.2. Eastern Europe Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antibody Fragments Market

• 22.1. Russia Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antibody Fragments Market

• 23.1. North America Antibody Fragments Market Overview
• 23.2. North America Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antibody Fragments Market

• 24.1. USA Antibody Fragments Market Overview
• 24.2. USA Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antibody Fragments Market

• 25.1. Canada Antibody Fragments Market Overview
• 25.2. Canada Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antibody Fragments Market

• 26.1. South America Antibody Fragments Market Overview
• 26.2. South America Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antibody Fragments Market

• 27.1. Brazil Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antibody Fragments Market

• 28.1. Middle East Antibody Fragments Market Overview
• 28.2. Middle East Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antibody Fragments Market

• 29.1. Africa Antibody Fragments Market Overview
• 29.2. Africa Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antibody Fragments Market Competitive Landscape And Company Profiles

• 30.1. Antibody Fragments Market Competitive Landscape
• 30.2. Antibody Fragments Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Antibody Fragments Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Biogen Inc.
• 31.9. UCB S.A.
• 31.10. Bio-Rad Laboratories Inc.
• 31.11. Genmab A/S
• 31.12. WuXi Biologics Co. Ltd.
• 31.13. Abcam plc
• 31.14. MacroGenics Inc.
• 31.15. Harbour BioMed

32. Global Antibody Fragments Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibody Fragments Market

34. Recent Developments In The Antibody Fragments Market

35. Antibody Fragments Market High Potential Countries, Segments and Strategies

• 35.1 Antibody Fragments Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antibody Fragments Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antibody Fragments Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34759_Antibody_Fragments_GMR_2025